The former Eli Lilly executive will be tasked with launching the biotech's anemia drug roxadustat.
News & Analysis: FibroGen
FGEN earnings call for the period ending September 30, 2019.
FibroGen reported highly anticipated clinical data on Friday for its lead drug roxadustat in chronic kidney disease.
FGEN earnings call for the period ending June 30, 2019.
FGEN earnings call for the period ending March 31, 2019.
The company reported confusing top-line results from an important batch of phase 3 safety studies. Were they successful?
April's about to shower biopharma investors with important updates that could move these stocks.
FGEN earnings call for the period ending December 31, 2018.
Even though the market fell, these stocks gained ground. Find out why.
Positive phase 2 data for the company's lung drug increases the biotech's value.